Download PDF
Thromb Haemost 2006; 96(01): 93-94
DOI: 10.1160/TH06-02-0123
Case Report
Schattauer GmbH

Extensive thromboembolic event as initial presentation of monoclonal gammopathy of undetermined significance

Marc Righini
1   Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Françoise Boehlen
1   Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Salah Gueddi
1   Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Grégoire Le Gal
2   Equipe d’accueil 3878 (GETBO) and Department of Internal Medicine and Chest Diseases, Brest University Hospital, France
,
Philippe de Moerloose
1   Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
› Author Affiliations
Further Information

Publication History

Received 28 February 2006

Accepted after resubmission 21 May 2006

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the “well” elderly. Am J Med 1987; 82: 39-45.
    CrossrefPubMedGoogle Scholar
  • 2 Kyle RA, Therneau TM, Rajkumar SV. et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-9.
    CrossrefPubMedGoogle Scholar
  • 3 Kyle RA, Therneau TM, Rajkumar SV. et al. A longterm study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-9.
    CrossrefPubMedGoogle Scholar
  • 4 Barlogie B, Jagannath S, Desikan KR. et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
    PubMedGoogle Scholar
  • 5 Srkalovic G, Elson P, Trebisky B. et al. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002; 19: 219-26.
    CrossrefPubMedGoogle Scholar
  • 6 Zangari M, Anaissie E, Barlogie B. et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
    CrossrefPubMedGoogle Scholar
  • 7 Zangari M, Siegel E, Barlogie B. et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.
    CrossrefPubMedGoogle Scholar
  • 8 Minnema MC, Fijnheer R, De Groot PG. et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 01: 445-9.
    CrossrefPubMedGoogle Scholar
  • 9 Sallah S, Husain A, Wan J. et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15: 1490-4.
    CrossrefPubMedGoogle Scholar
  • 10 Srkalovic G, Cameron MG, Rybicki L. et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101: 558-66.
    CrossrefPubMedGoogle Scholar
  • 11 White RH, Chew HK, Zhou H. et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165: 1782-7.
    CrossrefPubMedGoogle Scholar
  • 12 Rajkumar SV, Kyle RA, Therneau TM. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-7.
    CrossrefPubMedGoogle Scholar